Plain-English translation of NCT04290663 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Thyroid Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
After thyroid cancer surgery, doctors sometimes use radioactive iodine to destroy any remaining cancer cells. This trial is testing two different strategies for intermediate-risk thyroid cancer patients: one approach gives radioactive iodine to everyone, while the other uses blood tests and special scans to decide which patients actually need it. The goal is to figure out which approach works best and avoids unnecessary treatment.
Doctors aren't sure whether all intermediate-risk patients benefit from radioactive iodine treatment, since some may be cured by surgery alone. This trial aims to determine if doctors can safely avoid this treatment in patients who don't need it, based on test results, while still catching those who do.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group will receive radioactive iodine treatment routinely, while the other group will have blood tests and imaging scans to guide whether you need the treatment. Either way, you'll visit the clinic for follow-up appointments and testing over 5 years to monitor your health and watch for any cancer recurrence.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
France